Nemera is developing its pen injector platform and tailor to meet customer needs.
Radosław Romańczuk, MD, Pen Platform Business Development Director; Severine Duband, Category Director, Devices; and Audrey Chandra, Category Project Manager, all at Nemera, discuss the development of the company’s pen-injector platforms and how they are tailored to meet the customer’s needs.
The subcutaneous route of administration is highly preferable for many injectable drugs, such as trastuzumab, rituximab, bortezomib, granulocyte-colony stimulating factor (GCSF), immunoglobulins, epoetin alfa and heparin. For some drugs (e.g. insulin), the choice of administration route depends on the clinical circumstances.
In order to increase patients’ compliance and adherence, as well as to accommodate pharmaceuticals’ needs, developing a device platform needs to be strategically defined to ensure that it is designed for the maximum possible range of potential therapeutic areas and patient populations. This is to ultimately assure the device effectiveness.
Innovative technological solutions that offer a simple and intuitive user interface are easily adopted by patients. This favours adherence to therapy as well as safe and reliable dose delivery. Furthermore, successful technology can be applied to the development of other medical devices. By fostering the platform approach, coupled with Nemera’s integrated end-to-end service programme offerings, the company helps its customers accelerate their specific combination product development programmes in the sprint to market.
Nemera’s long-standing experience in the high-scale production of tailor-made pen injectors serves as a strong foundation and legacy that steers the company to go the extra mile, continuing its story.
Thanks in large part to the two strategic acquisitions made in the last couple of years, Nemera is well on its way to fulfilling its vision of becoming one of the most patient-centric drug delivery device companies worldwide.
To read the full article: Injectable Drug Delivery – April issue 120 – Nemera
To read the full magazine: Injectable Drug Delivery – April issue 120
About the author:
Radosław Romańczuk, MD, Pen Platform Business Development Director, has over 20 years of experience in the life sciences industry. He is the author of the concept of a series of pen injectors, produced by Copernicus, which was acquired by Nemera in 2020.
The development and usability of medical technologies is perceived by Dr Radoslaw in three dimensions, representing his versatile experience – the perspective of a medical doctor, the perspective of the person managing marketing and business development in a biotechnological company, and the perspective of a person in charge of development of pen injectors franchise within a patient-centric device manufacturing organisation.
Séverine Duband is Marketing Director for drug delivery Devices at Nemera, steering overall category strategy, product portfolio and innovation development for five key delivery routes. She has been leading the parenteral segment at Nemera since 2018, focusing on proprietary products such as safety systems, pen injectors and on-body injectors. Ms Duband graduated from Emlyon Business School (Lyon, France) in 2004, and joined Nemera’s Global Marketing team in 2018 as a Global Category Manager, focusing on the parenteral segment.
Audrey Chandra is the Category Project Manager at Nemera. She joined Nemera in 2019. Ms Chandra graduated from the Faculty of Medicine, Atma Jaya University (Jakarta, Indonesia) and pursued her master’s degree in strategy and business development at Toulouse School of Management (France). With her dual competencies, she is in charge of providing strategic support for various targeted marketing projects. Additionally,
Ms Chandra actively works on diverse content management along with communication activities co-ordination.
As a world-leading drug delivery device solutions provider, our purpose of putting patients first enables us to design and manufacture devices that maximize treatment efficacy. We are a holistic partner and help our customers succeed in the sprint to market of their combination products. From early device strategy to state-of-the-art manufacturing, we’re committed to the highest quality standards. Agile and open-minded, we work with our customers as colleagues. Together, we go the extra mile to fulfill our mission.
For more information, visit www.nemera.net